Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for gout

Area of Science:

• Genetics
• Pharmacology
• Rheumatology

Background:

• Gout is a common inflammatory arthritis caused by monosodium urate crystal deposition due to hyperuricemia.
• Existing urate-lowering therapies are insufficient for many patients, necessitating novel treatment strategies.
• Genome-wide Mendelian randomization (MR) offers a powerful approach to identify and validate druggable targets for complex diseases like gout.

Purpose of the Study:

• To identify novel, druggable genetic targets for gout using a genome-wide Mendelian randomization approach.
• To validate potential causal genes through replication, colocalization, and mechanistic analyses.
• To assess the therapeutic potential, including repurposing opportunities, of identified genes.

Main Methods:

• Two-sample Mendelian randomization (MR) integrating druggable genes with cis-eQTL data from human blood.
• Replication analysis in an independent gout Genome-Wide Association Study (GWAS) cohort.
• Further validation using SMR, HEIDI, Bayesian colocalization, mediation MR, and phenome-wide MR (Phe-MR).

Main Results:

• Identified three high-confidence druggable genes causally linked to gout: KAT5, THBS3, and MAP3K11.
• KAT5 showed a potential indirect effect on gout risk via uric acid levels, with minimal predicted adverse effects.
• MAP3K11 has existing approved therapeutics, indicating repurposing potential, while THBS3 and KAT5 represent novel targets.

Conclusions:

• KAT5, THBS3, and MAP3K11 are prioritized as therapeutic targets for gout based on robust genetic evidence.
• The findings provide valuable guidance for developing new gout therapeutics and repurposing existing drugs.
• This study highlights the utility of druggable genome-wide MR in accelerating the discovery of actionable targets for inflammatory arthritis.